| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Brentuximab vedotin |
| Brand | Adcetris® |
| Indication | Treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. |
| Assessment Process | |
| Rapid review commissioned | 28/11/2012 |
| Rapid review completed | 21/12/2012 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full submission received from Applicant | 16/09/2013 |
| NCPE assessment completed | 11/04/2014 |
| NCPE assessment outcome | Reimbursement not Recommended |
December 2015
The HSE has approved reimbursement following confidential price negotiations.
